Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

Pediatr Infect Dis J. 1999 Mar;18(3):223-31. doi: 10.1097/00006454-199903000-00004.

Authors

H C Meissner¹, R C Welliver, S A Chartrand, B J Law, L E Weisman, H L Dorkin, W J Rodriguez

Affiliation

¹ Department of Pediatrics, New England Medical Center, Tufts University School of Medicine, Boston, Mass 02111, USA. cmeissner@es.nemc.org

PMID: 10093942
DOI: 10.1097/00006454-199903000-00004

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / pharmacokinetics
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Humans
Infant
Infant, Newborn
Infant, Premature
Palivizumab
Respiratory Syncytial Virus Infections / prevention & control*
Respiratory Syncytial Viruses / immunology*
Risk Factors

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Palivizumab